|Articles|April 1, 2007

Oncology NEWS International

Oncology NEWS International Vol 16 No 4
Volume 16
Issue 4

Updated Varian Brachytherapy Applicator Receives Clearance

PALO ALTO, CaliforniaFDA has granted Varian Medical Systems 510K clearance to market its Esophagus Bougie Set, a brachytherapy applicator designed specifically for intraluminal treatment of esophageal cancer. According to Varian, the new technology allows optimal positioning of the applicator set in reference to the tissue being treated and can be used with Varian's full range of VariSoruce and GammaMed HDR afterloaders.

Articles in this issue

over 19 years ago

Article

Curcumin Evaluated for the Treatment of Pancreatic Cancer

over 19 years ago

Article

Tykerb Approved for Metastatic HER2+ Breast Cancer

over 19 years ago

Article

'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients

over 19 years ago

Article

Drug for BPH May Also Reduce the Risk of Prostate Cancer

over 19 years ago

Article

Phase III Trial of Prostvac-VF Is Launched

over 19 years ago

Article

Electronic System Reminds Patients to Schedule Exams

over 19 years ago

Article

Phase II Trial of Panzem for Renal Cell Carcinoma Initiated

over 19 years ago

Article

Chemotherapy May Enrich Tumorigenic Cells in Breast Ca

over 19 years ago

Article

Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway

over 19 years ago

Article

Watchful Waiting Management for Prostate Ca a Hard Sell

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Latest CME

Virtual Event

Missouri Oncology Society

2 Sessions are Available!

Virtual Event

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Updated Varian Brachytherapy Applicator Receives Clearance

Articles in this issue

Related Content

18 Advanced Oncoplastic Breast Surgery Using Multiple Pedicles Following Breast-Conserving Surgery: Oncologic and Surgical Outcomes

19 Targeted Axillary Dissection—Does the Biopsy-Proven Node Need to Be Localized? A Retrospective Review of Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy

Improving Luspatercept Titration and Persistence in Community Practice

EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process

How Multidisciplinary Care and Molecular Diagnostics Are Redefining Ocular Oncology

Latest CME

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Arkansas Association of Cancer Professionals

Rhode Island Oncology Society

Kentucky Society of Clinical Oncology

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Empire State Hematology & Oncology Society (New York)

South Carolina Oncology Society

Minnesota Society of Clinical Oncology

West Virginia Oncology Society

North Carolina Oncology Association

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Kansas Society of Clinical Oncology

Colorado Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Wyoming State Oncology Society

Montana State Oncology Society

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Optimizing Treatment for Biliary Tract Cancers

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Arizona Clinical Oncology Society

Nevada Oncology Society

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

9th Annual School of Nursing Oncology™

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Diagnosis and Management of TGCT

Optimizing Multidisciplinary Care in TGCT

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care